LJX192
Total Payments
$380,523
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $380,523 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $380,523 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FIRST IN HUMAN RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF LLG783 IN HEALTHY SUBJECTS | Novartis Pharmaceuticals Corporation | $380,523 | 0 |
Top Doctors Receiving Payments for LJX192
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Wilmington, NC | $380,523 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $380,523
Product Information
- Type Drug
- Total Payments $380,523
- Total Doctors 0
- Transactions 1
About LJX192
LJX192 is a drug associated with $380,523 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2017. In 2017, $380,523 was paid across 1 transactions to 0 doctors.
The most common payment nature for LJX192 is "Unspecified" ($380,523, 100.0% of total).
LJX192 is associated with 1 research study, including "A FIRST IN HUMAN RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF LLG783 IN HEALTHY SUBJECTS" ($380,523).